Funk A, Katerji M, Afifi M, Nyswaner K, Woodroofe C, Edwards Z
bioRxiv. 2024; .
PMID: 39605563
PMC: 11601640.
DOI: 10.1101/2024.11.19.623840.
Lu X, Jin J, Wu Y, Lin J, Zhang X, Lu S
Bioact Mater. 2024; 43:255-272.
PMID: 39386219
PMC: 11461841.
DOI: 10.1016/j.bioactmat.2024.09.022.
Loy C, Trader D
RSC Chem Biol. 2024; 5(9):877-883.
PMID: 39211472
PMC: 11352960.
DOI: 10.1039/d4cb00148f.
Ortiz Zacarias N, Roth S, Broekhuis J, van der Es D, Moreau K, Heitman L
Int J Mol Sci. 2024; 25(16).
PMID: 39201670
PMC: 11354370.
DOI: 10.3390/ijms25168984.
Feng Y, Hu X, Wang X
Biomark Res. 2024; 12(1):85.
PMID: 39169396
PMC: 11340087.
DOI: 10.1186/s40364-024-00638-1.
Cyclosporin A-Based PROTACs Can Deplete Abundant Cellular Cyclophilin A without Suppressing T Cell Activation.
Hilbig K, Towers R, Schmitz M, Bornhauser M, Lennig P, Zhang Y
Molecules. 2024; 29(12).
PMID: 38930843
PMC: 11206246.
DOI: 10.3390/molecules29122779.
New-generation advanced PROTACs as potential therapeutic agents in cancer therapy.
Wang C, Zhang Y, Chen W, Wu Y, Xing D
Mol Cancer. 2024; 23(1):110.
PMID: 38773495
PMC: 11107062.
DOI: 10.1186/s12943-024-02024-9.
Tissue distribution and retention drives efficacy of rapidly clearing VHL-based PROTACs.
Zhang D, Ma B, Dragovich P, Ma L, Chen S, Chen E
Commun Med (Lond). 2024; 4(1):87.
PMID: 38755248
PMC: 11099041.
DOI: 10.1038/s43856-024-00505-y.
Orally Bioavailable Proteolysis-Targeting Chimeras: An Innovative Approach in the Golden Era of Discovering Small-Molecule Cancer Drugs.
Rej R, Rao Allu S, Roy J, Acharyya R, Kiran I, Addepalli Y
Pharmaceuticals (Basel). 2024; 17(4).
PMID: 38675453
PMC: 11054475.
DOI: 10.3390/ph17040494.
Development and crystal structures of a potent second-generation dual degrader of BCL-2 and BCL-xL.
Nayak D, Lv D, Yuan Y, Zhang P, Hu W, Nayak A
Nat Commun. 2024; 15(1):2743.
PMID: 38548768
PMC: 10979003.
DOI: 10.1038/s41467-024-46922-4.
"PROTAC" modified dihydroquinolizinones (DHQs) that cause degradation of PAPD-5 and inhibition of hepatitis A virus and hepatitis B virus, in vitro.
Li Y, Hwang N, Snedeker A, Lemon S, Noe D, Sun L
Bioorg Med Chem Lett. 2024; 102:129680.
PMID: 38428537
PMC: 11155259.
DOI: 10.1016/j.bmcl.2024.129680.
Recent Advances in Optically Controlled PROTAC.
Ouyang M, Feng Y, Chen H, Liu Y, Tan C, Tan Y
Bioengineering (Basel). 2023; 10(12).
PMID: 38135959
PMC: 10740939.
DOI: 10.3390/bioengineering10121368.
WWP1 E3 ligase at the crossroads of health and disease.
Behera A, Reddy A
Cell Death Dis. 2023; 14(12):853.
PMID: 38129384
PMC: 10739765.
DOI: 10.1038/s41419-023-06380-0.
Small Molecule Inhibitors Targeting the "Undruggable" Survivin: The Past, Present, and Future from a Medicinal Chemist's Perspective.
Cui Q, Huang C, Liu J, Zhang J
J Med Chem. 2023; 66(24):16515-16545.
PMID: 38092421
PMC: 11588358.
DOI: 10.1021/acs.jmedchem.3c01130.
Optimization of small molecule degraders and antagonists for targeting estrogen receptor based on breast cancer: current status and future.
Yao J, Tao Y, Hu Z, Li J, Xue Z, Zhang Y
Front Pharmacol. 2023; 14:1225951.
PMID: 37808197
PMC: 10551544.
DOI: 10.3389/fphar.2023.1225951.
Central Nervous System Targeted Protein Degraders.
Thomas B, Lewis H, Jones D, Ward S
Biomolecules. 2023; 13(8).
PMID: 37627229
PMC: 10452695.
DOI: 10.3390/biom13081164.
KRAS G12D and G12V Mediated by CANDDY Technology Independent of Ubiquitination.
Miyamoto-Sato E, Imanishi S, Huang L, Itakura S, Iwasaki Y, Ishizaka M
Molecules. 2023; 28(14).
PMID: 37513471
PMC: 10386196.
DOI: 10.3390/molecules28145600.
DNA framework-engineered chimeras platform enables selectively targeted protein degradation.
Zhou L, Yu B, Gao M, Chen R, Li Z, Gu Y
Nat Commun. 2023; 14(1):4510.
PMID: 37495569
PMC: 10372072.
DOI: 10.1038/s41467-023-40244-7.
Pan-cancer analysis reveals the prognostic and immunologic roles of cereblon and its significance for PROTAC design.
Zhang S, Zeng N, Sun J, Liu C, Xu J, Xu M
Heliyon. 2023; 9(6):e16644.
PMID: 37303568
PMC: 10248115.
DOI: 10.1016/j.heliyon.2023.e16644.
PROTACs: Emerging Targeted Protein Degradation Approaches for Advanced Druggable Strategies.
Sincere N, Anand K, Ashique S, Yang J, You C
Molecules. 2023; 28(10).
PMID: 37241755
PMC: 10224132.
DOI: 10.3390/molecules28104014.